India, Sept. 14 -- O ur body is made of cells, and cancer can arise from any cell. Similarly, cancer arising from blood cells (like lymphoid and myeloid cells) is called blood cancer, and it is of 3 types, viz. Lymphoma, leukaemia and myeloma. The main symptoms of blood cancer are severe generalised weakness, unexplained persistent fever, bruises or bleeding from gums, nose or GI tract, bone or joint pains, lymph node enlargement, etc. Early recognition of these signs and symptoms is very important in suspecting blood cancer early. Usually, for these symptoms, the physician should get a CBC done, which can pick up the blood cancer early. Once it is suspected, the patient should immediately consult the hemato-oncologist to confirm the diagnosis, and it usually requires a bone marrow test or lymph node biopsy and then specialised tests to confirm the type of blood cancer. Not every blood cancer is treated the same way. Early diagnosis and early initiation of treatment are the keys for a successful outcome and preventing complications. Moreover, most of the blood cancers are curable. For diagnosis, qualified hematopathologists are required with facilities for performing flow cytometry, immunohistochemistry, and molecular and genetic diagnostics. Usually, the blood cancers are treated at specialised centres where all the facilities are available, like specialised diagnostics, blood bank support, radiation oncology support, interventional radiology and ICU backup. Specialised trained nurses who are capable of handling sick neutropenic patients, cytotoxic chemotherapy drugs and central lines are a must for handling hemato-oncology patients. Usually, blood cancers are treated by chemotherapy with or without targeted therapy or immunotherapies. Many blood cancers also require bone marrow transplants as the modality for cure. For BMT, a fully HLA-matched family donor is required, as it will have the best outcomes in terms of better disease control and fewer complications. But for those patients who do not have a full HLA-matched donor, haplo-identical (half-match) BMT or matched unrelated donor (MUD) BMT are also options with outcomes almost similar to full-matched donor BMT. T cell deplete haplo using MACS technology for selecting the desired cells from the stem cell harvest products has revolutionised the Haplo BMT with great success. There have been great advances in recent years which have resulted in improved outcomes and even achieved permanent cure in blood cancers. Recently CAR-T cell therapy has also improved survival in many multiple relapsed/refractory blood cancers. With the availability of CAR-T cell therapy in India at much cheaper rates, this treatment modality has given hope to many patients who failed multiple lines of therapy. Blood cancers are curable provided they are treated by trained hemato-oncologists at specialised centres....